PriceTargets.com logo

Seaport Therapeutics - SPTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $35.50
  • Forecasted Upside: 97.11%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$18.01 As of 05/26/2026 11:22 AM ET
▲ +0.51 (2.91%)

This chart shows the closing price for SPTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Seaport Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SPTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SPTX

Analyst Price Target is $35.50
▲ +97.11% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Seaport Therapeutics in the last 3 months. The average price target is $35.50, with a high forecast of $42.00 and a low forecast of $30.00. The average price target represents a 97.11% upside from the last price of $18.01.

This chart shows the closing price for SPTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 investment analysts is to moderate buy stock in Seaport Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/26/2026

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/26/2026CitigroupInitiated CoverageBuy$35.00
5/26/2026BNP Paribas ExaneDowngradeMarket Perform
5/26/2026Stifel NicolausSet TargetBuy$30.00
5/26/2026JPMorgan Chase & Co.Initiated CoverageOverweight$42.00
5/26/2026Leerink PartnersInitiated CoverageOutperform$35.00
(Data available from 5/26/2021 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2026
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/26/2026

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.

Seaport Therapeutics

Read More

Today's Range

Now: $18.01
Low: $17.32
High: $18.25

50 Day Range

MA: N/A

52 Week Range

Now: $18.01
Low: $14.85
High: $23.00

Volume

35,285 shs

Average Volume

394,124 shs

Market Capitalization

$955.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Seaport Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Seaport Therapeutics in the last year: BNP Paribas Exane, Citigroup Inc., JPMorgan Chase & Co., Leerink Partners, Seaport Research Partners, Stifel Nicolaus, and Wall Street Zen.
View the latest analyst ratings for SPTX.

What is the current price target for Seaport Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Seaport Therapeutics in the last year. Their average twelve-month price target is $35.50, suggesting a possible upside of 99.4%. JPMorgan Chase & Co. has the highest price target set, predicting SPTX will reach $42.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $30.00 for Seaport Therapeutics in the next year.
View the latest price targets for SPTX.

What is the current consensus analyst rating for Seaport Therapeutics?

Seaport Therapeutics currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SPTX.